CD86 and neoplasm: In conclusion, tumor immunity was different according to the neoadjuvant therapy method and response, with CD86, CD4, and t/iCD8 expression, but not CTLA-4 and sCD8 expression, being significantly higher in the nCT-treated and poor response groups.